Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY ‐ CVR study
Authors' conclusion
Baseline ALT is a potential predictor of differential efficacy between dapagliflozin and sitagliptin in T2DM, independent of BMI. Lower ALT correlated with enhanced sitagliptin efficacy, whereas higher ALT favoured dapagliflozin for glycaemic control.
Study context
- Population
- Patients with T2D on metformin monotherapy or no treatment, Japan
- Participants
- 340 patients
- Comparison
- Dapagliflozin vs sitagliptin by baseline ALT level
- Primary endpoint
- Co-primary: HbA1c and time in range
- Follow-up
- 24 weeks
Methodological detailspost hoc analysis, latent class analysis, open-label
- Post hoc analysis
- Latent class analysis
- Open-label
Primary result
As reported in the abstract
- Lower ALT: better response to sitagliptin; higher ALT: enhanced efficacy with dapagliflozin, across all models
- p < 0.05
Further findings
Interactions between ALT, body mass index (BMI) and HbA1c (regression)
- Significant interactions between ALT, BMI and HbA1c
- P = 0.02, 0.03
Correlation of baseline ALT with HbA1c change
- Total cohort
- P = 0.03
- Sitagliptin
- P < 0.01
Original publication
Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY ‐ CVR study. Diabetes Obes Metab. Published 25 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →